García-Lledó Javier, Cortejoso Lucía, Tenorio Núñez María, Giménez-Manzorro Alvaro, Matilla-Peña Ana, Salcedo-Plaza Magdalena, Sanjurjo-Sáez María
Departments of 1Gastroenterology and Hepatology and 2Pharmacy, Hospital General Universitario Gregorio Marañón, Madrid, Spain; and 3Department of Hematology, Hospital Ramón y Cajal, Madrid, Spain.
Am J Ther. 2014 Sep-Oct;21(5):e169-70. doi: 10.1097/MJT.0b013e318274df35.
We report a case of a 55-year-old male with chronic hepatitis C virus infection and compensated liver disease treated with sorafenib for advanced hepatocarcinoma (Barcelona Clinic Liver Cancer stage C). At follow-up, the patient developed hypertension, which was well controlled with beta-blocker medication, and an aortic dilation detected by abdominal computerized tomography and echocardiography. There are some reports of the side effects of sorafenib on the cardiovascular system. The patient had no cardiac or aortic pathology before the start of this palliative chemotherapy. There is an article that describes the development of an aortic aneurysm in a patient with uncontrolled hypertension, who received treatment with sorafenib for renal carcinoma. However, our patient had a good control of blood pressure. The adverse vascular effects of Sorafenib may be due to the inhibition of the proliferation of vascular endothelial muscle cells. We believe that this case illustrates a probable relationship between sorafenib and aortic dilatation according to the Karch and Lasagna causality algorithm.
我们报告了一例55岁男性慢性丙型肝炎病毒感染且肝功能代偿患者，其因晚期肝癌（巴塞罗那临床肝癌分期C期）接受索拉非尼治疗。在随访过程中，患者出现高血压，使用β受体阻滞剂药物可良好控制，同时通过腹部计算机断层扫描和超声心动图检测到主动脉扩张。有一些关于索拉非尼对心血管系统副作用的报道。该患者在开始这种姑息化疗前无心脏或主动脉病变。有一篇文章描述了一名高血压未得到控制的患者在接受索拉非尼治疗肾癌后发生主动脉瘤。然而，我们的患者血压控制良好。索拉非尼的不良血管效应可能是由于抑制了血管内皮肌细胞的增殖。根据卡奇和拉萨尼亚因果关系算法，我们认为该病例说明了索拉非尼与主动脉扩张之间可能存在的关系。
